Cadila gets USFDA nod for Pyridostigmine Bromide tablets

The company has received final approval from the US Food and Drug Administration (USFDA) to market Pyridostigmine Bromide Tablets USP, 60 mg, Zydus Cadila said in a filing to BSE.

June 24, 2015 / 13:12 IST

26 Aug, 2025 12:21

Volume

Todays L/H

Drug firm Zydus Cadila has received approval from the US health regulator to market its Pyridostigmine Bromide Tablets, used for treating various neurological disorders.

With this approval, the group has received 100 approvals and has so far filed 260 ANDAs (abbreviated new drug applications).

The company has received final approval from the US Food and Drug Administration (USFDA) to market Pyridostigmine Bromide Tablets USP, 60 mg, Zydus Cadila said in a filing to BSE.

According to IMS Health data, the estimated sales in 2015 for these tablets was USD 27.9 million.

Shares of Zydus Cadila were trading at Rs 1,774.50 on BSE, up 2.48 percent in the early morning trade.

first published: Jun 24, 2015 12:19 pm

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Subscribe to Tech Newsletters

Al Edge Newsletter On Saturdays

Find the best of Al News in one place, specially curated for you every weekend.
MC Tech 3 Newsletter Daily-Weekdays

Stay on top of the latest tech trends and biggest startup news.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347